Among these ADC candidates, Inotuzumab ozogamicin, an anti-CD22 calicheamicin conjugate developed by Pfizer, has started its Phase III study in treating relapsed and refractory acute lymphoblastic leukemia (ALL), and is expected to be launched in 2017. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.